Patrick Vallance, President - R&D, GlaxoSmithKline said the company is looking forward to more collaborations and is looking at a number of options to move ahead with its expansion plans.
In an interview to CNBC-TV18’s Vikas Dandekar, Patrick Vallance, President - R&D said the company, which has been in India for several decades, is looking forward to more collaborations and is considering a number of options to move ahead with its expansion plans.
Vallance added that it already has tie-ups with a number of companies in India and has its own R&D centers in Bangalore and Mumbai.
He said GSK has a very strong relationship with IT major Tata Consultancy Services (TCS) and GVK BIO.
According to Vallance, things have been very impressive so far and GSK is increasingly looking towards India to make progress in science-based supply to drug discovery.
Vallance said there are India has some really outstanding scientists and can pave a way forward towards drug discovery.
“One of the things that I am going to go back from this trip is thinking how good are we at actually scouting and connectivity, because we do need to better at our connectivity both in terms with emerging companies but also with what is happening in the academic institutes and the strong science base here, just to make sure we have got our right connections”, he said.